GKOS Quote, Financials, Valuation and Earnings

Globus Medical, Inc. has a net margin of -93.39% compared to Glaukos Corp.'s net margin of 15.47%. Glaukos Corp.'s return on equity of -25.22% beat Globus Medical, Inc.'s return on equity of 10.08%.

Glaukos Corp. has a consensus price target of $134.38, signalling upside risk potential of 11.06%. On the other hand Globus Medical, Inc. has an analysts' consensus of $107.17 which suggests that it could grow by 18.88%. Given that Globus Medical, Inc. has higher upside potential than Glaukos Corp., analysts believe Globus Medical, Inc. is more attractive than Glaukos Corp..

Glaukos Corp. has a beta of 0.705, which suggesting that the stock is 29.528% less volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.056, suggesting its more volatile than the S&P 500 by 5.621%.

Glaukos Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Glaukos Corp. pays -- of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend.

Glaukos Corp. quarterly revenues are $143.1M, which are smaller than Globus Medical, Inc. quarterly revenues of $769M. Glaukos Corp.'s net income of -$133.7M is lower than Globus Medical, Inc.'s net income of $119M. Notably, Glaukos Corp.'s price-to-earnings ratio is -- while Globus Medical, Inc.'s PE ratio is 29.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Glaukos Corp. is 13.64x versus 4.49x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of -93.39% compared to Glaukos Corp.'s net margin of 27.89%. Glaukos Corp.'s return on equity of -25.22% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Glaukos Corp. has a consensus price target of $134.38, signalling upside risk potential of 11.06%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 22.18%. Given that Intuitive Surgical, Inc. has higher upside potential than Glaukos Corp., analysts believe Intuitive Surgical, Inc. is more attractive than Glaukos Corp..

Glaukos Corp. has a beta of 0.705, which suggesting that the stock is 29.528% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.653, suggesting its more volatile than the S&P 500 by 65.303%.

Glaukos Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Glaukos Corp. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

Glaukos Corp. quarterly revenues are $143.1M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Glaukos Corp.'s net income of -$133.7M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Glaukos Corp.'s price-to-earnings ratio is -- while Intuitive Surgical, Inc.'s PE ratio is 63.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Glaukos Corp. is 13.64x versus 18.05x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -93.39% compared to Glaukos Corp.'s net margin of -316.61%. Glaukos Corp.'s return on equity of -25.22% beat Plus Therapeutics, Inc.'s return on equity of --.

Glaukos Corp. has a consensus price target of $134.38, signalling upside risk potential of 11.06%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1843.46%. Given that Plus Therapeutics, Inc. has higher upside potential than Glaukos Corp., analysts believe Plus Therapeutics, Inc. is more attractive than Glaukos Corp..

Glaukos Corp. has a beta of 0.705, which suggesting that the stock is 29.528% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Glaukos Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Glaukos Corp. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Glaukos Corp. quarterly revenues are $143.1M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Glaukos Corp.'s net income of -$133.7M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Glaukos Corp.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Glaukos Corp. is 13.64x versus 4.54x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ResMed, Inc. has a net margin of -93.39% compared to Glaukos Corp.'s net margin of 27.59%. Glaukos Corp.'s return on equity of -25.22% beat ResMed, Inc.'s return on equity of 25.44%.

Glaukos Corp. has a consensus price target of $134.38, signalling upside risk potential of 11.06%. On the other hand ResMed, Inc. has an analysts' consensus of $297.47 which suggests that it could grow by 14.89%. Given that ResMed, Inc. has higher upside potential than Glaukos Corp., analysts believe ResMed, Inc. is more attractive than Glaukos Corp..

Glaukos Corp. has a beta of 0.705, which suggesting that the stock is 29.528% less volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.869, suggesting its less volatile than the S&P 500 by 13.099%.

Glaukos Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed, Inc. offers a yield of 0.9% to investors and pays a quarterly dividend of $0.60 per share. Glaukos Corp. pays -- of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Glaukos Corp. quarterly revenues are $143.1M, which are smaller than ResMed, Inc. quarterly revenues of $1.4B. Glaukos Corp.'s net income of -$133.7M is lower than ResMed, Inc.'s net income of $392.6M. Notably, Glaukos Corp.'s price-to-earnings ratio is -- while ResMed, Inc.'s PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Glaukos Corp. is 13.64x versus 7.04x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.